NCT00486356 2024-01-03
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
University of Nebraska
Phase 1 Completed
Clinical Trials
8 trialsNCT03111732 2021-12-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00483405 2017-07-12
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00604409 2015-09-07
Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer
Fox Chase Cancer Center
Phase 1 Completed
NCT02013830 2014-06-06
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00363584 2013-08-26
Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00021047 2012-03-08
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00076609 2007-03-28
Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
PhytoCeutica
Phase 1/2 Completed